Collecting and evaluating convalescent plasma for COVID‐19 treatment: why and how? - Archive ouverte HAL Access content directly
Journal Articles Vox Sanguinis Year : 2020

Collecting and evaluating convalescent plasma for COVID‐19 treatment: why and how?

(1, 2) , (3) , (1, 2) , (1, 3) , (4, 5) , (6, 7)
1
2
3
4
5
6
7

Abstract

Plasma provided by COVID-19 convalescent patients may provide therapeutic relief as the number of COVID-19 cases escalates steeply worldwide. Prior findings in various viral respiratory diseases including SARS-CoV-related pneumonia suggest that convalescent plasma can reduce mortality, although formal proof of efficacy is still lacking. By reducing viral spread early on, such an approach may possibly downplay subsequent immunopathology. Identifying, collecting, qualifying and preparing plasma from convalescent patients with adequate SARS-CoV-2-neutralizing Ab titres in an acute crisis setting may be challenging, although well within the remit of most blood establishments. Careful clinical evaluation should allow to quickly establish whether such passive immunotherapy, administered at early phases of the disease in patients at high risk of deleterious evolution, may reduce the frequency of patient deterioration, and thereby COVID-19 mortality.

Dates and versions

inserm-02569986 , version 1 (11-05-2020)

Identifiers

Cite

Pierre Tiberghien, Xavier de Lamballerie, Pascal Morel, Pierre Gallian, Karine Lacombe, et al.. Collecting and evaluating convalescent plasma for COVID‐19 treatment: why and how?. Vox Sanguinis, 2020, ⟨10.1111/vox.12926⟩. ⟨inserm-02569986⟩
74 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More